Arctic Bioscience — AGM Information 2025

May 12, 2025

Arctic Bioscience - Notice of Annual General Meeting on 26 May 2025

Arctic Bioscience - Notice of Annual General Meeting on 26 May 2025

Arctic Bioscience AS' Annual General Meeting will be held Monday 26 May 2025 at

11:00 (CET), as a digital meeting.

Shareholders are encouraged to cast their votes in advance of the General

Meeting or grant the Chair of the Board a proxy, with or without voting

instructions.

The deadline for registration of attendance, advance votes, proxy or

instructions is 22 May 2025 at 16:00 (CET). For attendance at the live event,

please follow the instructions in the notice.

For further information, see the attached Notice of the Annual General Meeting,

which can also be accessed from the company's website (https://arctic

-bioscience.com/investors/general-meetings/).

Board of Directors proposal:

Proposed board members for the next period are:

· Harald Nordal (chairperson) (reelection)

· Jan Endre Vartdal (reelection)

· Tore A. F. Tønseth (reelection)

· Marita Holstad (reelection)

· Olav Sindre Kriken (new)

Proposed new board member Olav Sindre Kriken is a Norwegian citizen from Ørsta

based in Palo Alto, California. Mr. Kriken is an experienced Founder and

Businessman with a solid record within business innovation and growth. He is

skilled in Product-Led Growth, Business Modelling, Marketing Management and

Digital Strategy. The nomination of Mr. Kriken to the company board is aligned

with the company growth within product sales through established and new

distributions channels with strategic utilization of the opportunities with AI

and SoMe.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.